Also under the new boss Jonathan Pratt stands the bad biotech icon for sale. On the candidate list: fresh names from the private equity scene. If it goes fast, especially Pratt's predecessor Thierry Bernard benefits.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Also under the new boss Jonathan Pratt stands the bad biotech icon for sale. On the candidate list: fresh names from the private equity scene. If it goes fast, especially Pratt's predecessor Thierry Bernard benefits.